Clinical Advances in Pharmacotherapy for Acute Kawasaki Disease

Kawasaki disease (KD) is an acute, self-limiting vasculitis that predominantly affects children under 5 years old. The precise etiology and pathogenesis of KD remain incompletely understood. This multisystem disorder represents the most common cause of acquired heart disease in children and may lead to coronary artery lesions (CALs), with severe complications including myocardial infarction and sudden cardiac death. Consequently, standardized treatment during the acute phase is of paramount importance to reduce coronary complications. This article focuses on recent advances in pharmacotherapy for acute-phase KD, aiming to inform clinical management strategies.